Skip to content
Emirates Drug Establishment
-
Emirates Drug Establishment signals shift in obesity care with approval of once-daily oral orforglipron
The drug works as a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, requiring no food or water restrictions before taking it.
-
Emirates Drug Establishment approves Inpefa for heart failure
Inpefa is the first dual SGLT1 and SGLT2 inhibitor approved specifically for heart failure treatment.
-
Emirates Drug Establishment hosts forum to advance UAE clinical research
The forum aimed to strengthen the UAE’s position as a premier regional hub for clinical research while demonstrating the nation’s dedication to building a healthcare ecosystem driven by knowledge and innovation.